What You Need To Know
- EValuate Diagnostics, a spin-out company from the Hackensack Meridian Health Research Institute and its Office of Innovation and Commercialization, has received a $1 million commitment from the Foundation Venture Capital Group (FVCG’s), an affiliate of the New Jersey Health Foundation (NJHF), to advance a new platform for the targeted capture of circulating biomarkers, known as extracellular vesicles (EVs).
- Olivier Loudig, Ph.D., an associate member of the Hackensack Meridian Center for Discovery and Innovation (CDI), is directly involved with the development of EValuate Diagnostics.
- His laboratory at the CDI has developed research programs for biomarker discovery and early detection of breast, lung, and prostate cancers using liquid biopsies and has been able to detect RNA signatures indicative of a developing cancer in blood and other biofluids.
Breakthrough in detection of novel biomarkers
The selection of circulating EVs for disease detection has been elusive to medicine thus far, but technological advances in their isolation and analysis of molecular cargos are enabling the detection of novel biomarkers.
Diagnostic assays derived from this technology will help monitor disease biomarkers for earlier-than-ever detection of tumors and a wide range of other diseases.